nodes	percent_of_prediction	percent_of_DWPC	metapath
Lubiprostone—CLCN2—endothelium—melanoma	0.118	0.278	CbGeAlD
Lubiprostone—CLCN2—blood vessel—melanoma	0.109	0.256	CbGeAlD
Lubiprostone—CLCN2—eye—melanoma	0.058	0.136	CbGeAlD
Lubiprostone—CLCN2—head—melanoma	0.0329	0.0774	CbGeAlD
Lubiprostone—CBR1—eye—melanoma	0.0233	0.0546	CbGeAlD
Lubiprostone—CLCN2—lymph node—melanoma	0.0231	0.0542	CbGeAlD
Lubiprostone—CBR1—skin of body—melanoma	0.0202	0.0475	CbGeAlD
Lubiprostone—CBR1—mammalian vulva—melanoma	0.0185	0.0433	CbGeAlD
Lubiprostone—Colitis ischaemic—Docetaxel—melanoma	0.0144	0.0274	CcSEcCtD
Lubiprostone—CBR1—head—melanoma	0.0132	0.031	CbGeAlD
Lubiprostone—Faecal incontinence—Carmustine—melanoma	0.013	0.0248	CcSEcCtD
Lubiprostone—Faecal incontinence—Temozolomide—melanoma	0.0126	0.024	CcSEcCtD
Lubiprostone—CBR1—lymph node—melanoma	0.00924	0.0217	CbGeAlD
Lubiprostone—Pharyngolaryngeal pain—Docetaxel—melanoma	0.00627	0.0119	CcSEcCtD
Lubiprostone—Laryngeal pain—Docetaxel—melanoma	0.00621	0.0118	CcSEcCtD
Lubiprostone—Oedema peripheral—Vemurafenib—melanoma	0.00616	0.0117	CcSEcCtD
Lubiprostone—Connective tissue disorder—Vemurafenib—melanoma	0.00614	0.0117	CcSEcCtD
Lubiprostone—Mediastinal disorder—Vemurafenib—melanoma	0.00563	0.0107	CcSEcCtD
Lubiprostone—CBR1—NRF2 pathway—SLC39A12—melanoma	0.00545	0.111	CbGpPWpGaD
Lubiprostone—Malnutrition—Vemurafenib—melanoma	0.00544	0.0104	CcSEcCtD
Lubiprostone—Erythema—Vemurafenib—melanoma	0.00544	0.0104	CcSEcCtD
Lubiprostone—Swelling—Carmustine—melanoma	0.00542	0.0103	CcSEcCtD
Lubiprostone—Dysgeusia—Vemurafenib—melanoma	0.00533	0.0101	CcSEcCtD
Lubiprostone—Lethargy—Dactinomycin—melanoma	0.00521	0.00992	CcSEcCtD
Lubiprostone—Chest discomfort—Docetaxel—melanoma	0.00478	0.0091	CcSEcCtD
Lubiprostone—Cough—Vemurafenib—melanoma	0.00475	0.00904	CcSEcCtD
Lubiprostone—Myalgia—Vemurafenib—melanoma	0.00463	0.00882	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.0046	0.00876	CcSEcCtD
Lubiprostone—Aspartate aminotransferase increased—Dactinomycin—melanoma	0.0046	0.00875	CcSEcCtD
Lubiprostone—Nervous system disorder—Vemurafenib—melanoma	0.00435	0.00829	CcSEcCtD
Lubiprostone—Skin disorder—Vemurafenib—melanoma	0.00431	0.00821	CcSEcCtD
Lubiprostone—Aspartate aminotransferase increased—Temozolomide—melanoma	0.00416	0.00792	CcSEcCtD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—ABCB5—melanoma	0.00408	0.0827	CbGpPWpGaD
Lubiprostone—Alanine aminotransferase increased—Temozolomide—melanoma	0.00407	0.00776	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00405	0.0077	CcSEcCtD
Lubiprostone—Abdominal distension—Temozolomide—melanoma	0.00402	0.00765	CcSEcCtD
Lubiprostone—Decreased appetite—Vemurafenib—melanoma	0.00386	0.00735	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Vemurafenib—melanoma	0.00383	0.0073	CcSEcCtD
Lubiprostone—Fatigue—Vemurafenib—melanoma	0.00383	0.00729	CcSEcCtD
Lubiprostone—Constipation—Vemurafenib—melanoma	0.0038	0.00723	CcSEcCtD
Lubiprostone—Pollakiuria—Temozolomide—melanoma	0.00369	0.00702	CcSEcCtD
Lubiprostone—Weight increased—Temozolomide—melanoma	0.00363	0.00692	CcSEcCtD
Lubiprostone—Urinary tract infection—Carmustine—melanoma	0.00358	0.00682	CcSEcCtD
Lubiprostone—Swelling—Docetaxel—melanoma	0.00348	0.00663	CcSEcCtD
Lubiprostone—Urinary tract infection—Temozolomide—melanoma	0.00346	0.00659	CcSEcCtD
Lubiprostone—Erythema—Bleomycin—melanoma	0.0033	0.00628	CcSEcCtD
Lubiprostone—Hypersensitivity—Vemurafenib—melanoma	0.00327	0.00623	CcSEcCtD
Lubiprostone—Oedema peripheral—Carmustine—melanoma	0.00326	0.0062	CcSEcCtD
Lubiprostone—Connective tissue disorder—Carmustine—melanoma	0.00325	0.00619	CcSEcCtD
Lubiprostone—Asthenia—Vemurafenib—melanoma	0.00319	0.00607	CcSEcCtD
Lubiprostone—Oedema peripheral—Temozolomide—melanoma	0.00315	0.00599	CcSEcCtD
Lubiprostone—Connective tissue disorder—Temozolomide—melanoma	0.00314	0.00598	CcSEcCtD
Lubiprostone—Lethargy—Docetaxel—melanoma	0.00313	0.00597	CcSEcCtD
Lubiprostone—CBR1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—melanoma	0.00312	0.0632	CbGpPWpGaD
Lubiprostone—Erythema—Dactinomycin—melanoma	0.00307	0.00585	CcSEcCtD
Lubiprostone—Ill-defined disorder—Bleomycin—melanoma	0.00306	0.00582	CcSEcCtD
Lubiprostone—Diarrhoea—Vemurafenib—melanoma	0.00304	0.00579	CcSEcCtD
Lubiprostone—Malaise—Bleomycin—melanoma	0.00297	0.00566	CcSEcCtD
Lubiprostone—Dizziness—Vemurafenib—melanoma	0.00294	0.00559	CcSEcCtD
Lubiprostone—Mental disorder—Carmustine—melanoma	0.0029	0.00551	CcSEcCtD
Lubiprostone—Mediastinal disorder—Temozolomide—melanoma	0.00288	0.00548	CcSEcCtD
Lubiprostone—Malnutrition—Carmustine—melanoma	0.00288	0.00548	CcSEcCtD
Lubiprostone—Erythema—Carmustine—melanoma	0.00288	0.00548	CcSEcCtD
Lubiprostone—Cough—Bleomycin—melanoma	0.00288	0.00548	CcSEcCtD
Lubiprostone—Ill-defined disorder—Dactinomycin—melanoma	0.00285	0.00543	CcSEcCtD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—ARL2—melanoma	0.00282	0.0573	CbGpPWpGaD
Lubiprostone—Vomiting—Vemurafenib—melanoma	0.00282	0.00538	CcSEcCtD
Lubiprostone—Chest pain—Bleomycin—melanoma	0.00281	0.00534	CcSEcCtD
Lubiprostone—Myalgia—Bleomycin—melanoma	0.00281	0.00534	CcSEcCtD
Lubiprostone—Rash—Vemurafenib—melanoma	0.0028	0.00533	CcSEcCtD
Lubiprostone—Mental disorder—Temozolomide—melanoma	0.0028	0.00533	CcSEcCtD
Lubiprostone—Dermatitis—Vemurafenib—melanoma	0.0028	0.00533	CcSEcCtD
Lubiprostone—Headache—Vemurafenib—melanoma	0.00278	0.0053	CcSEcCtD
Lubiprostone—Malnutrition—Temozolomide—melanoma	0.00278	0.0053	CcSEcCtD
Lubiprostone—Erythema—Temozolomide—melanoma	0.00278	0.0053	CcSEcCtD
Lubiprostone—Discomfort—Bleomycin—melanoma	0.00277	0.00528	CcSEcCtD
Lubiprostone—Malaise—Dactinomycin—melanoma	0.00277	0.00528	CcSEcCtD
Lubiprostone—Cramp muscle—Docetaxel—melanoma	0.00276	0.00527	CcSEcCtD
Lubiprostone—Aspartate aminotransferase increased—Docetaxel—melanoma	0.00276	0.00527	CcSEcCtD
Lubiprostone—Dysgeusia—Temozolomide—melanoma	0.00272	0.00519	CcSEcCtD
Lubiprostone—Alanine aminotransferase increased—Docetaxel—melanoma	0.00271	0.00516	CcSEcCtD
Lubiprostone—Tremor—Carmustine—melanoma	0.0027	0.00513	CcSEcCtD
Lubiprostone—Oedema—Bleomycin—melanoma	0.00269	0.00512	CcSEcCtD
Lubiprostone—CBR1—NRF2 pathway—EPHA2—melanoma	0.00266	0.054	CbGpPWpGaD
Lubiprostone—Nausea—Vemurafenib—melanoma	0.00264	0.00502	CcSEcCtD
Lubiprostone—Myalgia—Dactinomycin—melanoma	0.00262	0.00498	CcSEcCtD
Lubiprostone—Tremor—Temozolomide—melanoma	0.00261	0.00496	CcSEcCtD
Lubiprostone—Discomfort—Dactinomycin—melanoma	0.00259	0.00492	CcSEcCtD
Lubiprostone—Ill-defined disorder—Temozolomide—melanoma	0.00258	0.00491	CcSEcCtD
Lubiprostone—Anorexia—Bleomycin—melanoma	0.00256	0.00488	CcSEcCtD
Lubiprostone—Oedema—Dactinomycin—melanoma	0.00251	0.00478	CcSEcCtD
Lubiprostone—Malaise—Temozolomide—melanoma	0.00251	0.00478	CcSEcCtD
Lubiprostone—CBR1—NRF2 pathway—SLC6A11—melanoma	0.0025	0.0507	CbGpPWpGaD
Lubiprostone—CBR1—Arachidonic acid metabolism—CYP1B1—melanoma	0.0025	0.0506	CbGpPWpGaD
Lubiprostone—Palpitations—Temozolomide—melanoma	0.00246	0.00468	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Bleomycin—melanoma	0.00245	0.00467	CcSEcCtD
Lubiprostone—Chest pain—Carmustine—melanoma	0.00245	0.00467	CcSEcCtD
Lubiprostone—Myalgia—Carmustine—melanoma	0.00245	0.00467	CcSEcCtD
Lubiprostone—Anxiety—Carmustine—melanoma	0.00244	0.00465	CcSEcCtD
Lubiprostone—Cough—Temozolomide—melanoma	0.00243	0.00462	CcSEcCtD
Lubiprostone—Weight increased—Docetaxel—melanoma	0.00242	0.0046	CcSEcCtD
Lubiprostone—Dyspnoea—Bleomycin—melanoma	0.0024	0.00457	CcSEcCtD
Lubiprostone—Anorexia—Dactinomycin—melanoma	0.00239	0.00455	CcSEcCtD
Lubiprostone—Myalgia—Temozolomide—melanoma	0.00237	0.00451	CcSEcCtD
Lubiprostone—Anxiety—Temozolomide—melanoma	0.00236	0.00449	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.00235	0.00448	CcSEcCtD
Lubiprostone—Oedema—Carmustine—melanoma	0.00235	0.00447	CcSEcCtD
Lubiprostone—Discomfort—Temozolomide—melanoma	0.00234	0.00445	CcSEcCtD
Lubiprostone—Decreased appetite—Bleomycin—melanoma	0.00234	0.00445	CcSEcCtD
Lubiprostone—Dry mouth—Temozolomide—melanoma	0.00232	0.00441	CcSEcCtD
Lubiprostone—Pain—Bleomycin—melanoma	0.0023	0.00438	CcSEcCtD
Lubiprostone—Tachycardia—Carmustine—melanoma	0.00229	0.00436	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Dactinomycin—melanoma	0.00229	0.00435	CcSEcCtD
Lubiprostone—Oedema—Temozolomide—melanoma	0.00227	0.00432	CcSEcCtD
Lubiprostone—Anorexia—Carmustine—melanoma	0.00224	0.00426	CcSEcCtD
Lubiprostone—Nervous system disorder—Temozolomide—melanoma	0.00223	0.00424	CcSEcCtD
Lubiprostone—Feeling abnormal—Bleomycin—melanoma	0.00222	0.00422	CcSEcCtD
Lubiprostone—Skin disorder—Temozolomide—melanoma	0.0022	0.0042	CcSEcCtD
Lubiprostone—Hyperhidrosis—Temozolomide—melanoma	0.00219	0.00418	CcSEcCtD
Lubiprostone—Decreased appetite—Dactinomycin—melanoma	0.00218	0.00415	CcSEcCtD
Lubiprostone—Fatigue—Dactinomycin—melanoma	0.00216	0.00412	CcSEcCtD
Lubiprostone—Anorexia—Temozolomide—melanoma	0.00216	0.00412	CcSEcCtD
Lubiprostone—Pain—Dactinomycin—melanoma	0.00215	0.00409	CcSEcCtD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—SLC15A2—melanoma	0.00214	0.0434	CbGpPWpGaD
Lubiprostone—Musculoskeletal discomfort—Carmustine—melanoma	0.00214	0.00407	CcSEcCtD
Lubiprostone—Dyspnoea—Carmustine—melanoma	0.00209	0.00399	CcSEcCtD
Lubiprostone—Oedema peripheral—Docetaxel—melanoma	0.00209	0.00399	CcSEcCtD
Lubiprostone—Connective tissue disorder—Docetaxel—melanoma	0.00209	0.00398	CcSEcCtD
Lubiprostone—Feeling abnormal—Dactinomycin—melanoma	0.00207	0.00394	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Temozolomide—melanoma	0.00207	0.00394	CcSEcCtD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—SLC17A5—melanoma	0.00206	0.0418	CbGpPWpGaD
Lubiprostone—Gastrointestinal pain—Dactinomycin—melanoma	0.00205	0.00391	CcSEcCtD
Lubiprostone—Decreased appetite—Carmustine—melanoma	0.00204	0.00389	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Carmustine—melanoma	0.00203	0.00386	CcSEcCtD
Lubiprostone—Dyspnoea—Temozolomide—melanoma	0.00202	0.00385	CcSEcCtD
Lubiprostone—Constipation—Carmustine—melanoma	0.00201	0.00382	CcSEcCtD
Lubiprostone—Pain—Carmustine—melanoma	0.00201	0.00382	CcSEcCtD
Lubiprostone—Dyspepsia—Temozolomide—melanoma	0.002	0.0038	CcSEcCtD
Lubiprostone—Abdominal pain—Dactinomycin—melanoma	0.00198	0.00378	CcSEcCtD
Lubiprostone—Hypersensitivity—Bleomycin—melanoma	0.00198	0.00377	CcSEcCtD
Lubiprostone—Decreased appetite—Temozolomide—melanoma	0.00197	0.00376	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Temozolomide—melanoma	0.00196	0.00373	CcSEcCtD
Lubiprostone—Fatigue—Temozolomide—melanoma	0.00196	0.00373	CcSEcCtD
Lubiprostone—Pain—Temozolomide—melanoma	0.00194	0.0037	CcSEcCtD
Lubiprostone—Constipation—Temozolomide—melanoma	0.00194	0.0037	CcSEcCtD
Lubiprostone—Feeling abnormal—Carmustine—melanoma	0.00194	0.00369	CcSEcCtD
Lubiprostone—Asthenia—Bleomycin—melanoma	0.00193	0.00368	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Carmustine—melanoma	0.00192	0.00366	CcSEcCtD
Lubiprostone—Mediastinal disorder—Docetaxel—melanoma	0.00191	0.00365	CcSEcCtD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—SLC6A11—melanoma	0.00187	0.038	CbGpPWpGaD
Lubiprostone—Feeling abnormal—Temozolomide—melanoma	0.00187	0.00356	CcSEcCtD
Lubiprostone—Mental disorder—Docetaxel—melanoma	0.00186	0.00354	CcSEcCtD
Lubiprostone—Abdominal pain—Carmustine—melanoma	0.00186	0.00354	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Temozolomide—melanoma	0.00186	0.00353	CcSEcCtD
Lubiprostone—Malnutrition—Docetaxel—melanoma	0.00185	0.00352	CcSEcCtD
Lubiprostone—Erythema—Docetaxel—melanoma	0.00185	0.00352	CcSEcCtD
Lubiprostone—Hypersensitivity—Dactinomycin—melanoma	0.00185	0.00352	CcSEcCtD
Lubiprostone—Dysgeusia—Docetaxel—melanoma	0.00181	0.00345	CcSEcCtD
Lubiprostone—Asthenia—Dactinomycin—melanoma	0.0018	0.00343	CcSEcCtD
Lubiprostone—Abdominal pain—Temozolomide—melanoma	0.00179	0.00342	CcSEcCtD
Lubiprostone—Muscle spasms—Docetaxel—melanoma	0.00178	0.00339	CcSEcCtD
Lubiprostone—Hypersensitivity—Carmustine—melanoma	0.00173	0.00329	CcSEcCtD
Lubiprostone—Diarrhoea—Dactinomycin—melanoma	0.00172	0.00327	CcSEcCtD
Lubiprostone—Vomiting—Bleomycin—melanoma	0.00171	0.00326	CcSEcCtD
Lubiprostone—Rash—Bleomycin—melanoma	0.0017	0.00323	CcSEcCtD
Lubiprostone—Dermatitis—Bleomycin—melanoma	0.00169	0.00323	CcSEcCtD
Lubiprostone—Asthenia—Carmustine—melanoma	0.00168	0.00321	CcSEcCtD
Lubiprostone—Hypersensitivity—Temozolomide—melanoma	0.00167	0.00318	CcSEcCtD
Lubiprostone—Syncope—Docetaxel—melanoma	0.00166	0.00316	CcSEcCtD
Lubiprostone—Palpitations—Docetaxel—melanoma	0.00163	0.00311	CcSEcCtD
Lubiprostone—Asthenia—Temozolomide—melanoma	0.00163	0.0031	CcSEcCtD
Lubiprostone—Loss of consciousness—Docetaxel—melanoma	0.00163	0.0031	CcSEcCtD
Lubiprostone—Cough—Docetaxel—melanoma	0.00161	0.00307	CcSEcCtD
Lubiprostone—Diarrhoea—Carmustine—melanoma	0.00161	0.00306	CcSEcCtD
Lubiprostone—Nausea—Bleomycin—melanoma	0.0016	0.00304	CcSEcCtD
Lubiprostone—Vomiting—Dactinomycin—melanoma	0.0016	0.00304	CcSEcCtD
Lubiprostone—Rash—Dactinomycin—melanoma	0.00158	0.00301	CcSEcCtD
Lubiprostone—Myalgia—Docetaxel—melanoma	0.00157	0.003	CcSEcCtD
Lubiprostone—Chest pain—Docetaxel—melanoma	0.00157	0.003	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.00156	0.00298	CcSEcCtD
Lubiprostone—Dizziness—Carmustine—melanoma	0.00155	0.00296	CcSEcCtD
Lubiprostone—Diarrhoea—Temozolomide—melanoma	0.00155	0.00296	CcSEcCtD
Lubiprostone—Dry mouth—Docetaxel—melanoma	0.00154	0.00293	CcSEcCtD
Lubiprostone—Oedema—Docetaxel—melanoma	0.00151	0.00287	CcSEcCtD
Lubiprostone—Dizziness—Temozolomide—melanoma	0.0015	0.00286	CcSEcCtD
Lubiprostone—Vomiting—Carmustine—melanoma	0.00149	0.00284	CcSEcCtD
Lubiprostone—Nausea—Dactinomycin—melanoma	0.00149	0.00284	CcSEcCtD
Lubiprostone—Shock—Docetaxel—melanoma	0.00148	0.00283	CcSEcCtD
Lubiprostone—Rash—Carmustine—melanoma	0.00148	0.00282	CcSEcCtD
Lubiprostone—Nervous system disorder—Docetaxel—melanoma	0.00148	0.00282	CcSEcCtD
Lubiprostone—Dermatitis—Carmustine—melanoma	0.00148	0.00282	CcSEcCtD
Lubiprostone—Tachycardia—Docetaxel—melanoma	0.00147	0.00281	CcSEcCtD
Lubiprostone—Headache—Carmustine—melanoma	0.00147	0.0028	CcSEcCtD
Lubiprostone—Skin disorder—Docetaxel—melanoma	0.00147	0.00279	CcSEcCtD
Lubiprostone—Vomiting—Temozolomide—melanoma	0.00144	0.00275	CcSEcCtD
Lubiprostone—Anorexia—Docetaxel—melanoma	0.00144	0.00274	CcSEcCtD
Lubiprostone—Rash—Temozolomide—melanoma	0.00143	0.00272	CcSEcCtD
Lubiprostone—Dermatitis—Temozolomide—melanoma	0.00143	0.00272	CcSEcCtD
Lubiprostone—Headache—Temozolomide—melanoma	0.00142	0.00271	CcSEcCtD
Lubiprostone—Nausea—Carmustine—melanoma	0.00139	0.00266	CcSEcCtD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—ACER3—melanoma	0.00139	0.0282	CbGpPWpGaD
Lubiprostone—Musculoskeletal discomfort—Docetaxel—melanoma	0.00137	0.00262	CcSEcCtD
Lubiprostone—Nausea—Temozolomide—melanoma	0.00135	0.00257	CcSEcCtD
Lubiprostone—Dyspnoea—Docetaxel—melanoma	0.00135	0.00256	CcSEcCtD
Lubiprostone—Dyspepsia—Docetaxel—melanoma	0.00133	0.00253	CcSEcCtD
Lubiprostone—Decreased appetite—Docetaxel—melanoma	0.00131	0.0025	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Docetaxel—melanoma	0.0013	0.00248	CcSEcCtD
Lubiprostone—Fatigue—Docetaxel—melanoma	0.0013	0.00248	CcSEcCtD
Lubiprostone—Pain—Docetaxel—melanoma	0.00129	0.00246	CcSEcCtD
Lubiprostone—Constipation—Docetaxel—melanoma	0.00129	0.00246	CcSEcCtD
Lubiprostone—Feeling abnormal—Docetaxel—melanoma	0.00124	0.00237	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Docetaxel—melanoma	0.00123	0.00235	CcSEcCtD
Lubiprostone—Abdominal pain—Docetaxel—melanoma	0.00119	0.00227	CcSEcCtD
Lubiprostone—CBR1—NRF2 pathway—SLC5A5—melanoma	0.00114	0.0232	CbGpPWpGaD
Lubiprostone—CBR1—Arachidonic acid metabolism—PTGS2—melanoma	0.00113	0.0228	CbGpPWpGaD
Lubiprostone—Hypersensitivity—Docetaxel—melanoma	0.00111	0.00212	CcSEcCtD
Lubiprostone—Asthenia—Docetaxel—melanoma	0.00108	0.00206	CcSEcCtD
Lubiprostone—Diarrhoea—Docetaxel—melanoma	0.00103	0.00197	CcSEcCtD
Lubiprostone—Dizziness—Docetaxel—melanoma	0.000998	0.0019	CcSEcCtD
Lubiprostone—Vomiting—Docetaxel—melanoma	0.00096	0.00183	CcSEcCtD
Lubiprostone—Rash—Docetaxel—melanoma	0.000952	0.00181	CcSEcCtD
Lubiprostone—Dermatitis—Docetaxel—melanoma	0.000951	0.00181	CcSEcCtD
Lubiprostone—Headache—Docetaxel—melanoma	0.000945	0.0018	CcSEcCtD
Lubiprostone—Nausea—Docetaxel—melanoma	0.000896	0.00171	CcSEcCtD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—SLC5A5—melanoma	0.000856	0.0174	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—HGF—melanoma	0.000847	0.0172	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PIP4K2A—melanoma	0.000843	0.0171	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—CUBN—melanoma	0.000703	0.0143	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—GPAM—melanoma	0.000658	0.0133	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—ABCB1—melanoma	0.000652	0.0132	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—ACER3—melanoma	0.000619	0.0126	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—UGT2B10—melanoma	0.000567	0.0115	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PLA2G6—melanoma	0.000559	0.0113	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—HS3ST5—melanoma	0.000527	0.0107	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—CYP17A1—melanoma	0.000424	0.0086	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—ALB—melanoma	0.000408	0.00828	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PLCB4—melanoma	0.000399	0.0081	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—FASN—melanoma	0.000392	0.00795	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PIP4K2A—melanoma	0.000375	0.00761	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—SLC6A11—melanoma	0.000375	0.00761	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—MTAP—melanoma	0.000365	0.0074	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—CYP1B1—melanoma	0.000357	0.00724	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—LUM—melanoma	0.000325	0.0066	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PHGDH—melanoma	0.000325	0.0066	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—HPSE—melanoma	0.000319	0.00647	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—CUBN—melanoma	0.000313	0.00635	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—BSG—melanoma	0.000303	0.00614	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—SDHD—melanoma	0.000303	0.00614	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—CSPG4—melanoma	0.000303	0.00614	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—GPAM—melanoma	0.000293	0.00594	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PLA2G6—melanoma	0.000249	0.00505	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—VCAN—melanoma	0.000224	0.00454	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	0.000212	0.0043	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PPARG—melanoma	0.000204	0.00415	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—CYP17A1—melanoma	0.000189	0.00383	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	0.000186	0.00378	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—ALB—melanoma	0.000184	0.00373	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—GNA11—melanoma	0.000178	0.00362	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—FASN—melanoma	0.000174	0.00354	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—SLC5A5—melanoma	0.000172	0.00348	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—GNAQ—melanoma	0.000166	0.00336	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—CD44—melanoma	0.000166	0.00336	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	0.000162	0.00329	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PTGS2—melanoma	0.000161	0.00326	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—CYP1B1—melanoma	0.000159	0.00322	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PTEN—melanoma	0.00014	0.00284	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—ABCB1—melanoma	0.000131	0.00265	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PRKCA—melanoma	0.00012	0.00244	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—ERCC2—melanoma	0.000119	0.00242	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	9.89e-05	0.00201	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PIK3CG—melanoma	9.43e-05	0.00191	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PPARG—melanoma	9.1e-05	0.00185	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PIK3CD—melanoma	8.29e-05	0.00168	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—ALB—melanoma	8.19e-05	0.00166	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PIK3CB—melanoma	7.23e-05	0.00147	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PTGS2—melanoma	7.16e-05	0.00145	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PTEN—melanoma	6.25e-05	0.00127	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PIK3CA—melanoma	4.41e-05	0.000894	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—AKT1—melanoma	3.6e-05	0.00073	CbGpPWpGaD
